State NM
Clinical Trials in New Mexico
Recruiting clinical trials with at least one study location in New Mexico. Data updated daily from ClinicalTrials.gov.
Top Conditions in New Mexico
NCT07006792 Phase 4
Recruiting
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Modera...
Condition
Atopic Dermatitis
Enrollment
200 pts
Location
United States, Argentina, Brazil
Sponsor
Eli Lilly and Company
NCT06866405 Phase 3
Recruiting
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vac...
Condition
RSV Infection
Enrollment
550 pts
Location
United States, Argentina, South Africa
Sponsor
Pfizer
NCT06679985 Phase 2
Recruiting
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Part...
Condition
Hepatocellular Carcinoma
Enrollment
72 pts
Location
United States, Australia, Canada
Sponsor
Coherus Oncology, Inc.
NCT06877884 N/A
Recruiting
A Prospective Registry to Enable Collection of Standardized Routine Care Oncolog...
Condition
Cancer
Enrollment
20,000 pts
Location
United States
Sponsor
N-Power Medicine
NCT03723928 N/A
Recruiting
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Re...
Condition
Anatomic Stage IV Breast Cancer AJCC v8
Enrollment
739 pts
Location
United States, Guam, Puerto Rico
Sponsor
SWOG Cancer Research Network
NCT02986984 N/A
Recruiting
Transformative Research in Diabetic Nephropathy
Condition
Diabetic Nephropathies
Enrollment
400 pts
Location
United States
Sponsor
University of Pennsylvania
NCT03511118 N/A
Recruiting
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breast...
Condition
Lactating Women on Select DOI
Enrollment
1,600 pts
Location
United States, Canada
Sponsor
Duke University
NCT05836987 Phase 3
Recruiting
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial F...
Condition
Atrial Fibrillation
Enrollment
5,350 pts
Location
United States
Sponsor
Johns Hopkins University
NCT05918861 Phase 3
Recruiting
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Rece...
Condition
Acute Coronary Syndrome
Enrollment
2,000 pts
Location
United States, Canada, Puerto Rico
Sponsor
DalCor Pharmaceuticals
NCT06498635 Phase 3
Recruiting
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After ...
Condition
Lung Non-Small Cell Carcinoma
Enrollment
306 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT03907046 Phase 3
Recruiting
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
Condition
Intracerebral Hemorrhage
Enrollment
700 pts
Location
United States
Sponsor
Yale University
NCT05112601 Phase 2
Recruiting
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System...
Condition
Endometrial Adenocarcinoma
Enrollment
81 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT05174169 Phase 2, Phase 3
Recruiting
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Condition
Stage III Colon Cancer
Enrollment
1,912 pts
Location
United States, Canada, Puerto Rico
Sponsor
NRG Oncology
NCT05642572 Phase 2
Recruiting
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer...
Condition
Recurrent Lung Non-Small Cell Carcinoma
Enrollment
66 pts
Location
United States
Sponsor
SWOG Cancer Research Network
NCT05126277 Phase 3
Recruiting
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With ...
Condition
Lupus Nephritis
Enrollment
462 pts
Location
United States, Argentina, Brazil
Sponsor
Novartis Pharmaceuticals
NCT06486428 N/A
Recruiting
Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies
Condition
Small-cell Lung Cancer
Enrollment
30 pts
Location
United States
Sponsor
Addario Lung Cancer Medical In
NCT06841354 Phase 3
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Comb...
Condition
Triple Negative Breast Neoplasms
Enrollment
1,000 pts
Location
United States, Argentina, Australia
Sponsor
Merck Sharp & Dohme LLC
NCT06500702 Phase 2
Recruiting
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzab...
Condition
Focal Segmental Glomerulosclerosis
Enrollment
84 pts
Location
United States, Argentina, Australia
Sponsor
Sanofi
NCT06749457 Phase 1, Phase 2
Recruiting
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase...
Condition
Staphylococcus Aureus
Enrollment
231 pts
Location
United States
Sponsor
AstraZeneca
NCT06203600 Phase 2, Phase 3
Recruiting
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophage...
Condition
Advanced Esophageal Adenocarcinoma
Enrollment
224 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT06933472 Phase 3
Recruiting
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosp...
Condition
Hyperphosphatemia
Enrollment
264 pts
Location
United States, China
Sponsor
Alebund Pharmaceuticals
NCT05806164 Phase 4
Recruiting
Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
Condition
Urgency Urinary Incontinence
Enrollment
432 pts
Location
United States
Sponsor
Women and Infants Hospital of
NCT06070350 Phase 3
Recruiting
Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage...
Condition
Hemorrhagic Shock
Enrollment
1,000 pts
Location
United States
Sponsor
Philip Spinella
NCT05591118 Phase 3
Recruiting
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
Condition
Pulmonary Embolism
Enrollment
500 pts
Location
United States
Sponsor
NYU Langone Health
NCT05489068 N/A
Recruiting
Motivational Interviewing at Intake vs Intake as Usual on Client Engagement in A...
Condition
Substance-Related Disorders
Enrollment
150 pts
Location
United States
Sponsor
University of New Mexico